Martin Shkreli Will Be A Guest On PreMarket Prep Tomorrow

Make sure you have a pot of coffee ready. Martin Shkreli will join PreMarket Prep for an exclusive interview on Monday at 8:15 a.m. ET.

Last week, Retrophin Inc (NASDAQ: RTRX) announced positive results from sparsentan, a mid-stage clinical trial in patients suffering from a rare kidney disease.

Shkreli is the co-founder and ex-CEO of Retrophin, but is faced charges of withholding information from investors. The Street's Adam Feuerstein credited Shkreli with designing the now-successful clinical trial. Feuerstein suggested that if the company's drug is approved, patients suffering from rare liver diseases "will have him to thank."

Related Link: Exclusive: Why Martin Shkreli Feels He Has Been Vindicated

In a phone call with Benzinga last week, Shkreli said he feels that sparsentan's success thus far vindicates him of his current price gouging criticism, as the company has spent more than $20 million to date on R&D to address those suffering from FSGS.

JMP analyst Liisa Bayko wrote in a note, "We believe that we will need to wait until year end to determine if [Retrophin] can convince the FDA that an accelerated approval pathway can meet the agency's needs."

If you have any questions for Shkreli or just want to tune in for the interview, click here.

Image: By House Committee on Oversight and Government Reform [Public domain], via Wikimedia Commons